Key facts
- This page summarizes John P. Schmid's Form 4 filing for Poseida Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jun 2024, 16:16.
John P. Schmid - 17 Jun 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jun 2024, 16:16:43 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 12 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry J.Leonhardt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John P. Schmid filed Form 4 for Poseida Therapeutics, Inc. on 18 Jun 2024.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PSTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +19,650
- Change %
- +50%
- Price
- $0.000000
- Shares after
- 58,950
- Date
- 17 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PSTX
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +27,350
- Change %
- Price
- $0.000000
- Shares after
- 27,350
- Date
- 17 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,350
- Exercise price
- $2.81
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.
Footnote F2
The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.